Levanta-se o pano: eis o novo visual da Seleção Portuguesa para a Copa do Mundo.

Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk. The Danish company is less diversified than current and future competitors, and increasingly exposed to ...

Just when you think Novo Nordisk A/S (NVO) can't go any lower, it gets some more bad news, and the stock dips further. The stock already collapsed in 2025 as GLP-1 enthusiasm faded and political ...

The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...

Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, hitting its ...

CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...

Novo Nordisk's next diabetes/weight loss medicine should be better than its current crown jewel. The Danish drugmaker is still facing some challenges, but its pipeline could get it out of trouble. Can ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knockoffs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the ...

Novo shares rise 5% after Hims scraps $49 weight‑loss pill FDA signals broader crackdown on compounded GLP-1 drugs Hims pulled its semaglutide-based pill after pushback Hims says lawsuit attacks ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of ...

Novo Nordisk was a leader in GLP-1 weight loss but was displaced by Eli Lilly. Investors have punished Novo Nordisk's stock, with the shares having lost more than half their value since mid-2024. Now ...